Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.81+0.34 (+1.39%)
Close on Nov 11, 2026Market cap $807.71MP/E 24.8Yield –
Collegium Pharmaceutical EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Collegium Pharmaceutical's EV/EBITDA was 4.3× on Nov 11, 2026, against 7.6× a year earlier. Over the last 5 years it ranged from 3.5× to 28.2×, with a median of 5.4×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.3× | −3.2 |
| 2025 | Dec 31, 2025 | 7.5× | +3.3 |
| 2024 | Dec 31, 2024 | 4.2× | −1.9 |
| 2023 | Dec 29, 2023 | 6.1× | −13.9 |
| 2022 | Apr 29, 2022 | 20.0× | +13.2 |
| 2021 | Dec 31, 2021 | 6.8× | −6.5 |
| 2020 | Dec 31, 2020 | 13.3× | – |
See a number that looks wrong?